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COMMENT
Standards of care in mesothelioma treatment
Susan V. Harden 1, Liz Darlison2, Paul Beckett3 and Anna C. Bibby4
The UK has the highest incidence of mesothelioma in the world, but services vary across the country partly due to uneven
geographical distribution of cases. The Mesothelioma UK-funded national organisational audit has highlighted challenges
in accessing diagnostic procedures such as thoracoscopy, as well as identifying examples of best practice, including access
to clinical trials and specialist therapeutic procedures. To ensure equitable and optimal patient care, cancer alliances should
have established referral pathways to specialist multidisciplinary team (MDT) services for discussion of all mesothelioma
patients.
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The UK has the highest incidence of mesothelioma worldwide,
with ~2700 cases diagnosed per year. The majority of newly
diagnosed people are aged 75 and above, and over 80% are men.
At least 90% of cases are preventable, caused by workplace
asbestos exposure decades previously.1 Despite these figures,
mesothelioma accounts for <1% of all new cancer cases in the UK,
with the number of new cases diagnosed per year in any one
hospital ranging from 1 to 40.2 To ensure that access to treatment
and care for mesothelioma patients is equitable across the
country, regardless of the number of cases seen in each centre,
it is important to have established regional referral pathways that
facilitate access to specialist services that may not be available
locally. With over 95% of mesothelioma arising in the pleural
cavity, the 2013 NHS England service specifications contract
recommended that “malignant mesothelioma services should be
provided by a combination of lung cancer multidisciplinary teams
and specialist mesothelioma multidisciplinary teams working in
collaboration”. It stated that “local and regional incidence of the
disease should be taken into account to ensure proper population
coverage”.3
Treatment options remain limited for mesothelioma and,
indeed, active oncologic treatment may not be appropriate for a
proportion of this patient cohort. However, for fit patients of good
performance status, standard first line systemic anti-cancer
therapy (SACT) of pemetrexed/cisplatin doublet has not changed
in the UK for over a decade. More recently, the addition of
bevacizumab, where available, has been shown to be beneficial.4,5
There is currently no National Institute for Health and Care
Excellence (NICE) approved second-line therapy. Clinical trials of
new therapies (including immunotherapy) are ongoing and, with
the highest incidence of cases worldwide, the UK is best placed to
deliver high-quality research in this area. Indeed the UK
has successfully run the only randomised trial investigating
the role of radical surgery in pleural mesothelioma,6 practice-
changing randomised trials demonstrating prophylactic
irradiation of intervention sites was not necessary.7,8 and the
University of Glasgow currently lead the PREDICT-Meso interna-
tional collaborative research initiative, part-funded by Cancer
Research UK.
Quality healthcare is not just about active oncologic treatment,
however, for optimal patient-centred outcomes, diagnostic
efficiency, pleural effusion management and access to specialist
supportive, palliative and end of life care are also important.
In recent years, the charity Mesothelioma UK has funded the
National Mesothelioma Audit, run by the Royal College of
Physicians, to report clinical outcomes and set quality indicators
and recommendations for mesothelioma care.2 This biennial audit
gives a national and regional picture of the numbers of
mesothelioma patients being diagnosed, of the treatments they
receive and of their survival outcomes. Since the publication of the
British Thoracic Society 2018 Mesothelioma Guidelines,9 the audit
has evaluated care across the UK against the standards set out in
this document. Although this is a useful tool for highlighting
variation around the country, it does not provide detail on how
services meet guideline recommendations, nor does it collect data
on diagnostic services or distinguish between local thoracic versus
specialist mesothelioma multidisciplinary team (MDT) discussion.
The recently published national mesothelioma organisational
audit was commissioned to obtain this information by collecting
data on the structure of mesothelioma services across the
country.10
All known thoracic cancer MDTs across England, Wales, Scot-
land and Northern Ireland were invited to take part in the
organisational audit. Questions were designed to obtain an
accurate picture of access to diagnostic, treatment and nursing
services for mesothelioma, and to identify those teams considered
specialist mesothelioma MDTs (defined as managing over 25 new
cases per year).9 An additional survey was completed by all 17
identified specialist mesothelioma MDTs as well as the national
peritoneal mesothelioma MDT at Basingstoke (~4% of UK
mesothelioma cases arise in the peritoneal cavity).2
At a local level, the biggest challenges identified by the
organisational audit were access to local anaesthetic thoracoscopy
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and insertion of intra-pleural catheters. These interventions are
important for obtaining a tissue diagnosis and as an option for
managing breathlessness in patients with symptomatic pleural
effusions.
Compared with local teams, patients referred to specialist
mesothelioma MDTs were more likely to have clinical stage and
histological subtype recorded; important factors in assessing
prognosis and clinical trial eligibility. Patients discussed at
specialist mesothelioma MDTs also had increased access to on-
site support from mesothelioma specialist nurses and opportu-
nities to participate in clinical trials. All specialist MDTs had direct
access to SACT and radiotherapy services, as well as established
pathways for onward referral of appropriate patients to the limited
number of UK centres offering radical debulking pleural surgery,
cytoreductive peritoneal surgery and palliative interventions such
as percutaneous cervical cordotomy.
In addition to these examples of best practice, the organisa-
tional audit identified several areas of variation between specialist
MDTs. There was a range in the number of mesothelioma cases
discussed, whether the mesothelioma MDT was held entirely
separately or as a section within a general thoracic MDT and the
extent of on-site specialist mesothelioma services offered.
Specifically, mesothelioma specialist nurses and palliative care
team members were not universally present in specialist
mesothelioma MDT meetings. Additionally, the availability of
teleconferencing facilities was considered beneficial to give
immediate feedback to referring teams but was underutilised by
specialist MDTs.
Recommendations from this first organisational audit of UK
mesothelioma services emphasise the importance of clear referral
pathways to a specialist mesothelioma MDT. Each cancer alliance
or region should have designated processes via which all
patients can be discussed at specialist MDT and are able to
access services that are not locally available. Specialist mesothe-
lioma MDTs, both current and future, should ensure that they are
able to offer patients access to all elements of guideline-
recommended treatment and the opportunity to participate in
clinical trials, as well as being able to provide rapid feedback to
referring teams.
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